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Summary Purpose: To establish the long-term efﬁcacy and tolerability of vagus nerve
stimulation (VNS) in children with a Lennox-like syndrome. Method: This study was a
longitudinal observational prospective cohort analysis. Baseline: 6 months. Follow-up:
24 months. Screening (baseline and every 6 months): MRI (baseline only), EEG, neu-
ropsychological evaluation, ECG and blood sampling for antiepileptic drug levels.
Nineteen children are included. Results: A seizure frequency reduction of 20.6% was
found at the end of the follow-up period. No relationship was detected between the
length of the stimulation period and the reduction in the seizure frequency. 21% of the
patients showed a reduction in seizure frequency of 50% or more. The seizure severity
showed improvement in the ﬁrst 12 months of treatment. The largest seizure reduc-
tion was found in the patients with highest frequency of background activity at the
baseline EEG. Neuropsychological ﬁndings: no negative impact on behaviour, mod-
erate improvement in function, behaviour and mood. Largest seizure reduction was
found in the group with the highest baseline mental function. The scores for mental
age improved independently of the seizure control. Twelve patients (63%) experi-
enced minor side effects, which subsided after 1 month. Conclusion: (1) There was
a signiﬁcant reduction in seizure frequency and severity. (2) No serious side effects
were recorded. (3) No negative effects on cognition or quality of life were apparent.
(4) Patients with highest baseline mental functioning showed the highest seizure re-
duction. (5) Those patients with less disturbed EEG (high background activity and less
interictal epileptic activity) showed the highest seizure reduction.
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Introduction
Epilepsy has a prevalence of 0.7—0.8%. Adequate
seizure control is achieved in only 75—80% of these
patients while 20—25% suffer from intractable
epilepsy.1 Vagal nerve stimulation (VNS)might be an
alternative treatment option as randomised studies
show a success rate of 12% in intractable epilepsy.
The success rate is deﬁned as the measured treat-
ment response rate corrected for placebo, measur-
ing bias and natural course, while the response rate
is deﬁned as a seizure frequency reduction of 50%
or more. This success rate is small but it is in line
with the success rates of new antiepileptic drugs in
pharmacotherapy resistant patients, which range
from 12 to 29%.2
Clinical trials in children
The effectiveness of VNS is positively correlated
to the duration of treatment, both in adults and
children.3,4—8
Hornig studied the effect of VNS in 19 children, 6
of them being diagnosed as having Lennox—Gastaut
syndrome.5 The preoperative baseline period was
1 month and the postoperative follow-up 21—29
months. He reported that ﬁve of the six children
showed a seizure frequency reduction of 90% or
more.
Parker presented the results of VNS in 16 children
with encephalopathic epilepsy.8 Ten of these chil-
dren were diagnosed as Lennox—Gastaut syndrome,
four suffered frommyoclonic epilepsy and two from
myoclonic astatic epilepsy. The situation 1 year af-
ter surgery was compared with a 2-month preoper-
ative baseline period. There was one drop out. Two
children showed an increase in seizure frequency
of more than 50% and four a decrease of more than
50%. The mean reduction was 17%. A similar study
was conducted by Lundgren et al.6 In this case, 16
children aged between 4 and 19 years were evalu-
ated during a baseline period of 6 months and the
results were compared with those from a treatment
period of 12—24 months. Eight children suffered
from partial seizures and eight from generalised
seizures; four of these were diagnosed as Lennox—
Gastaut syndrome. Six children (37%) showed a
reduction in seizure frequency of 50% or more;
one of them was diagnosed as Lennox—Gastaut
syndrome.
Ben Menachem reported the results of a prospec-
tive long-term open study with a follow-up of 3—64
months.4 The last 3 months of treatment with VNS
were compared with a preoperative baseline of 3
months. The subgroup of patients with Lennox—
Gastaut syndrome showed a mean reduction in
seizure frequency of 24%.
Nagarajan et al. studied the efﬁcacy of VNS in
children with refractory epilepsy.9 The children
showed multiple seizure characteristics and the
majority suffered from a moderate to severe men-
tal handicap. 62.5% achieved a seizure frequency
reduction of 50% or more; 25% of this prognosti-
cally unfavourable group achieved a seizure re-
duction of more than 90%. Similar results were
found by Zamponi et al. in a group of 13 chil-
dren with intractable epilepsy, multiple seizure
characteristics, mixed aetiology, and moderate
to severe mental handicap:10 66% of the children
showed a seizure frequency reduction of 50% or
more.
In these studies the reported side effects were
minor and most patients showed habituation. It
should be stressed that the reason for discontinuing
VNS was primarily due to insufﬁcient clinical results
and rarely due to side effects or complications of
treatment.2,3,11—14
In 1998, the Epilepsy Centre Kempenhaeghe and
the Neurosurgical Department of the University
Hospital Maastricht initiated a prospective study
in children with refractory epilepsy, diagnosed as
Lennox—Gastaut syndrome or Lennox-like types of
epilepsy.
The issues to be studied were the efﬁcacy and
tolerability of VNS in children with a Lennox—
Gastaut syndrome or Lennox-like type of epilepsy
in long-term follow-up.
Methods
VNS surgery and VNS stimulator
Bipolar stimulation of the vagus nerve was under-
taken by placing the electrodes around the left va-
gus nerve, while the pulse generator (Neurocyber-
netic prothesis NCP®, Cyberonics Inc., Webster, TX,
USA) is normally implanted below the clavicle.15
Because the group of children involved in this study
were mentally retarded and may show behavioural
problems, we chose to implant the device below
the pectoralis major to prevent them manipu-
lating the device and to give a more acceptable
cosmetic effect. All surgical procedures were per-
formed by the same neurosurgeon in the Maastricht
University Hospital (M.W.B.). The device was pro-
grammed telemetrically the day after the implan-
tation (H.J.M.M.) using the following parameters:
stimulation for 30 s followed by a stimulation-free
period of 3min, pulse width 500s, output cur-
rent 0.25mA. Over a period of 10—20 days, the
12 H.J.M. Majoie et al.
output current was increased by 0.25mA per day.
Should the patient experience side effects, such
as coughing or a tingling sensation in the throat,
the stepwise increase of the output current was
delayed for 1 or 2 days. Finally, all children were
stimulated with an output current of 1.5—2mA.
Should the effects of VNS not meet the expec-
tations of the parents after 3 months of treat-
ment, the stimulation parameters were changed.
As a result, 11 patients changed to so-called
‘rapid cycling’ (cycles of 7-s stimulation with a
stimulation-free interval of 18 s) during the subse-
quent 3-month period.
Stimulation can be switched off by placing a
handheld magnet over the generator. In chil-
dren who were prone to aspirate, the device was
switched off during their mealtimes.
Patient population
Nineteen children with malignant childhood
epilepsy resembling the Lennox—Gastaut syndrome
were included in this study. This clinical syndrome
is characterised by a large number of seizures and
therapy resistance.16,17
Inclusion criteria were:
1. Different seizure types, compatible with
Lennox—Gastaut syndrome;
2. Seizures are unacceptable to the patient;
3. Seizures cannot be treated in another way be-
cause of
• Ineffectiveness of ﬁrst and second choice
antiepileptic drugs;
• Unacceptable side effects of otherwise effec-
tive ﬁrst or second choice antiepileptic drugs;
4. Patients are not eligible for resective surgery or
callosotomy;
5. Disturbed background activity and slow spike-
waves on EEG;
6. Moderate or mild mental handicap;
7. Age 7—18 years;
8. Written and signed informed consent of parents.
Exclusion criteria:
1. Fast progressive neurodegenerative disease;
2. Ill-health contraindicating surgery;
3. Severe obstructive pulmonary disease, severe
disturbances of cardiac rhythm or severe stom-
ach disorder which are considered as contraindi-
cations for VNS.
Study design
The present study is a prospective longitudinal ob-
servational cohort analysis. The patients served
as their own controls. The baseline characteristics
were determined over an initial 6-month period.
After implantation and activation of the stimulator,
the patients were followed for 24 months.
During the ﬁrst 12 months, where ever possible,
no antiepileptic drug changes were permitted.
Medical outcome measures
During the 6 months prior to the implantation of
the device, data were collected from each pa-
tient to serve as a baseline. Follow-up measure-
ments were undertaken at 6, 12, 18 and 24 months
post-operatively. In this way, each patient served
as his or her own control.
Using the ILAE Classiﬁcation,18 the seizures
reported by the parents were categorised as
follows:
• Tonic seizures (drop-attacks with tonic contrac-
tion of the body–—the patient usually falls back-
wards);
• Atonic seizures (drop-attacks with complete re-
laxation of the body–—usually the patient drops
onto their knees, falls sideways or forwards);
• Myoclonic seizures (short-lived contractions of
the face or limbs);
• Tonic—clonic seizures (initial tonic contraction
of the body followed by regular shaking of the
limbs);
• Absences (short moments of decreased con-
sciousness with or without minor accompanying
symptoms).
The tonic, atonic, myoclonic and tonic—clonic
seizures were scored separately. A cluster of ﬁve or
more seizures were categorised as a series. Seizures
with a duration of 15min or more, and seizures re-
curring within 30min without full recovery of con-
sciousness, were coded as status epilepticus. The
absences were counted for a period of 1 h on the
same day of the week and at the same time. In the
week preceding the visit to the out-patient depart-
ment, the seizures were scored every day, at the
same time, and for a period of 1 h.
The seizure severity was scored with the
adapted Chalfont Severity Scales as described by
O’Donoghue.19
All children were given at least one, and max-
imally three, antiepileptic drugs. Generally, this
medication was not changed during the ﬁrst post-
operative 12 months. For two of the children the
following exceptions applied: discontinuation of
valproate (daily dose of 450mg) because of loss of
appetite and of lamotrigine (daily dose of 50mg)
because of behavioural problems.
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Neuropsychological outcome measures
To assess the effects of VNS on behaviour in the
present study, we deﬁned two separate domains,
namely, cognitive function and quality of life.
The assessment of cognitive functions aimed to
establish the mental age of the child using three
different tests depending on the level of function-
ing: the Dutch version of the Bayley Developmental
Scale20 (with scores ranging from 2 to 30 months
mental age); the McCarthy Developmental Scale21
(with score ranging from 2(1/2) to 8(1/2) years
mental age) and the WISC RN22 (with scores ranging
from 6 to 17 years mental age).
Quality of life was assessed by looking at areas of
functioning that are recognised in daily life, namely,
independence (using the SRZ Scale23), behaviour,
i.e. the tendency to develop behaviour disorders
(using the SGZ Scale24) and the mood characteris-
tics of the patient (using the TVZ Scale25). All scales
use proxy-scores (parents’ reports or, in the case of
in-patients, the nurses’ reports).
VNS was continues during testing. When con-
vulsive seizures occurred, the testing procedure
was postponed until the next day. When absence
seizures occurred, testing was stopped until the
parents (usually present during the testing session)
ascertained an optimal level of functioning.
Results
The study group consisted of 15 males and 4 females
at baseline, which reﬂects the predominance of
the male gender in patients suffering from epilepsy
(Table 1). The average age was 10.8 years, ranging
from 5.9 to 18.8 years. Most patients (16/19) were
treated on an out-patient basis, only 3 patients
were hospitalised. In 13 of the patients, the diagno-
sis of Lennox—Gastaut syndrome was conﬁrmed. Six
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Figure 1 Mean number of seizures per month.
patients had ‘Lennox-like’ syndromes: three had
Doose syndrome, one myoclonic absence epilepsy,
and two Dravet syndrome. The aetiology was known
in seven children (perinatal anoxia in four, dysplasia
in two and viral meningo-encephalitis in one). Mean
age of onset of the epilepsy was 2.2 years (with a
range of 0—8 years) and the average duration of
epilepsy was 8.1 years. All children had multiple
seizure types and treatment consisted of a broad
variety of antiepileptic drugs: valproate (n = 9),
carbamazepine (n = 7) and lamotrigine (n = 6)
were the most frequently used. Most patients were
on combination therapy (n = 16), ranging from two
to four antiepileptic drugs. Three patients were on
monotherapy (one oxcarbazepine, one lamotrigine
and one valproate).
Seizure frequency
The seizure frequency decreased by 50% or more
in four patients; one of these patients being
seizure-free. Eight patients showed a seizure re-
duction of less than 50% and six patients an increase
in seizure frequency. In total, 21% of the patients
showed a seizure reduction of 50% or more.
Fig. 1. shows the mean number of seizures per
month. Comparing baseline frequency with seizure
frequency at the end of the study a reduction
of 20.6% was found (Wilcoxon signed rank test,
P = 0.03). A positive relationship between the du-
ration of stimulation and seizure frequency reduc-
tion was not found. The seizure frequency for each
seizure type was also evaluated (Fig. 2.). Although
some seizure types seem to reacted better to VNS
than others, the differences were not signiﬁcant.
The seizure severity was scored with the adapted
Chalfont Seizure Severity Scale as presented by
O’Donoghue.19 The major improvements on this
scale were seen in the ﬁrst 12 months (Wilcoxon
signed rank test, P = 0.002).
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Table 1 Demographics and clinical characteristics of the study group.
ID Male (M)/
female (F)
Age at start
of the study
(years)
Age at onset
of seizures
(years)
Mental age
(years) at start
of the study
Syndrome Aetiology Seizure type MRI Reduction in
seizure
frequency (%)
1 M 7.9 1.5 1 Lennox—Gastaut Perinatal anoxia CPS/Ab/Myo/GTC/T Hemiatrophia dextra and hyperintensity right
hippocampus
<50
2 M 9.4 6 2 Doose Atypical fever convulsion CPS/SG (history: Myo) Normal >50
3 M 7.4 1.3 2.5 Doose Perinatal anoxia (forced
labour/arrythmia/meconium
in amniotic ﬂuid)/father is
known to have epilepsy
Ab/AT Normal Drop out
4 F 7.3 1.2 1 Lennox—Gastaut Unknown Ab/Myo/T Normal <50
5 M 11.3 1.6 0.17 Lennox—Gastaut Viral meningo-encephalitis Ab/T/GTC Hyperintensities cortical and subcortical (l > r);
dilated ventricles
<50
6 F 13.1 3 2.6 Lennox—Gastaut Double cortex syndrome CPS/AT/T Double cortex syndrome <50
7 M 5.9 0.02 0.1 Lennox—Gastaut Perinatal anoxia T (Ab and Myo—too
frequent to count)
Periventicular and cortical tissue loss with gliosis
(maximum in vertex regio and occipital)
Increase
8 M 11.9 0 0.2 Lennox—Gastaut Unknown Ab/Myo/GTC/T Tissue loss with wide sulci Increase
9 M 15.1 1.3 2.2 Lennox—Gastaut Unknown Myo/GTC/T Normal >50
10 M 14.9 8 0.2 Lennox—Gastaut Unknown Ab/GTC/T Normal <50
11 M 12.8 3 14.4 Myoclonic
absence epilepsy
Unknown Ab (history: AT) Normal >50
12 M 18.8 4.3 0.1 Lennox—Gastaut Unknown Ab/GTC Some loss of tissue around the left temporal horn,
otherwise normal
Unchanged
13 M 7.7 0 0.1 Lennox—Gastaut Microcephalia Ab/Myo/T Decreased amount of grey and white matter
occipitally and gray matter parietally, atrophia of
occipital corpus callosum, microcephalia
<50
14 M 13.8 2.7 2 Lennox—Gastaut Perinatal anoxia and fever
convulsion
CPS/Myo/GTC/T Parieto-occipital loss of white matter <50
15 F 11 3 7.6 Doose Unknown/positive family
history
CPS/Ab/Myo/GTC Normal >90
16a M 8.5 4 7.6 Lennox—Gastaut Unknown Ab/GTC/AT Normal <50
17 F 6.7 0.4 0.8 Dravet Unknown CPS/GTC Normal Increase
18 M 12 0 0.8 Lennox—Gastaut Dysgenesis GTC (history: Ab) Dysgenesis and hydrocephalus Unchanged
19 M 8.75 0.25 2.3 Dravet Unknown T Normal Unchanged
CPS: complex partial; SGTC: secondary generalised tonic—clonic; Ab: absence; Myo: myoclonic; GTC: generalised tonic—clonic; AT: atonic and T: tonic drop-attack.
a Patient No. 16 was diagnosed with Doose syndrome; however, in the last month prior to the start of the study evolution to Lennox—Gastaut syndrome was observed.
Vagus nerve stimulation in patients with catastrophic childhood epilepsy 15
Figure 2 Mean number of seizures per month recording
to seizure type.
EEG
EEG analyses at baseline showed that the fre-
quency of background activity was highest in re-
sponders (7.4Hz in responders versus 5.6Hz in
non-responders). The level of epileptic activity at
baseline was higher in non-responders than in re-
sponders, as was the minimal and maximal heart
rates (Table 2). However, the group of responders
was very small and so the differences did not reach
the level of statistical signiﬁcance.
Neuropsychological results
Table 3 shows the comparisons between baseline
and the follow-up period up to endpoint (24 months
Table 2 Minimal and maximal heart rate frequency at baseline while patient is awake and during sleep.
Mean minimal heart
rate frequency
(awake)
Mean maximal heart
rate frequency
(awake)
Mean minimal
heart rate
frequency (sleep)
Mean maximal
heart rate
frequency (sleep)
Responders (n = 4) 81 101 64 78
Non-responders (n = 14) 94 108 81 105
Table 3 Comparison of cognitive and quality of life outcomes; baseline versus endpoint.
Baseline,
mean (S.D.)
After 6 months
of VNS, mean
(S.D.)
After 12 months
of VNS, mean
(S.D.)
After 18 months
of VNS, mean
(S.D.)
After 24 months
of VNS, mean
(S.D.)
Cognition
Mental age (months) 30.2 (40.5) 32.8 (45.4) 33.2 (50.6) 33.2 (49.6) 34.4 (52.8)
Quality of life
Independence (SRZ score) 3.6 (1.4) 3.4 (1.6) 3.2 (1.1) 3.1 (1.1) 3.3 (1.0)
Behaviour (SGZ score) 6.6 (1.8) 6.9 (2.0) 7.0 (2.0) 6.9 (1.8) 7.3 (1.8)
Mood (TVZ score) 7.3 (2.9) 7.4 (3.5) 7.0 (3.3) 7.7 (2.6) 7.3 (3.0)
Scores for mental function age are in months. The scores for the ‘quality of life scales’ range from 3 to 9 (SRZ,
SGZ), 1 to 10 (TVZ). Higher scores represent better performance. Total change from baseline to endpoint for:
mental age= 4.2 months; ANOVA values: F 0.20; P = 0.99; independency= −0.3; Kruskall—Wallis Chi-square 1.309;
P = 0.86; behaviour = +0.7; Kruskall—Wallis Chi-square 1.318; P = 0.85; mood = 0; Kruskall—Wallis Chi-square
0.412; P = 0.98.
of stimulation) formental age and the three ‘quality
of life’ variables. No statistically signiﬁcant change
over timewas found for any of these comparisons. In
fact, all variables showed a similar proﬁle through-
out the follow-up period. The largest and most con-
sistent change was the increase of 4.2 months in
the mental age function from baseline to endpoint.
The group was subdivided according to overall re-
sponse (baseline to endpoint) to VNS treatment as
follows: >50% reduction in seizure frequency (re-
sponders), <50% reduction in seizure frequency, no
change or increase in seizure frequency (Table 4).
The three subgroups had statistically signiﬁ-
cant different levels of mental function (P = 0.04)
demonstrating that the response to the VNS varies
with level of mental function, the most positive
effects being seen in those patients with the high-
est level of mental functioning (89.3 months versus
15.0 and 20.3 months for the other two groups).
Complications and side effects
No surgical complications occurred. Many patients
suffered from side effects, but these effects were
minor and transient. These side effects included:
coughing (n = 4) and a strange feeling in the throat
described as a tickling sensation (n = 2) resolved
after the ﬁrst week of stimulation. Hoarseness,
only occurred during the time the patient was
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Table 4 Seizure reduction and mental age.
Seizure reduction Number of
patients
Mental age in
months, mean (S.D.)
Change of mental age from baseline
to endpoint in months, mean (S.D.)
Group 1: >50% reduction 4 89.3 (82.5) 12.3 (22.9)
Group 2: <50% reduction 7 15.0 (16.2) −0.9 (2.5)
Group 3: no reduction or
increase in seizure frequency
6 20.3 (36.6) 1.7 (5.7)
ANOVA for difference in mental age: F-value 3.873; P = 0.04; ANOVA for difference in ‘change of mental age’:
F-value 1.810; P = 0.20.
stimulated, was present in seven patients. This
side effect persisted until the second month of
stimulation. One patient encountered swallowing
difﬁculties. For this reason, the device was deacti-
vated during meals.
Discussion
This study evaluated the long-term efﬁcacy and
tolerability of VNS in a group of children with phar-
macotherapy resistant epilepsy. Our study showed
an average reduction in seizure frequency of 20.6%
after 24 months of treatment with VNS, which is,
while relatively modest, still comparable with the
results of the controlled VNS studies EO3 and EO5
(with an average reduction ranging from 24.5 to
27.9%).26,27 Twenty-one percent of the patients
showed a reduction in seizure frequency of 50% or
more; this is also compares favourably with the
EO3 and EO5 studies (31 and 23.4%, respectively).
This relatively modest reduction in seizure fre-
quency might be explained, at least partially, by
the speciﬁc patient group included, namely, those
with a severe type of refractory epilepsy and men-
tal retardation, multiple seizure types and a high
seizure frequency. The prognosis of the children
in this study group would be considered to be un-
favourable for normal treatment.16,17 In contrast,
the EO3 and EO5 studies related to a group of
patients aged 13—60 years (10% of these patients
were younger than 20 years) suffering from partial
seizures only (6 or more per month).28
The results are also comparable with earlier re-
ports on VNS in similar patient groups which showed
that 25% of the patients had a reduction in seizure
frequency of 50% or more, with a mean value for
the individual patient of about 20—30%.4,6,8,29
The results of the study by Hornig et al.5 are ex-
ceptional in that ﬁve of six patients with Lennox—
Gastaut syndrome showed a reduction in seizure
frequency of 90% or more. However, in that study
the baseline period of 1 month might have been too
short to be representative of the natural course of
the epilepsy in which case the patients could have
been recruited during a temporary exacerbation of
their epilepsy and to have returned to their mean
seizure frequency during treatment with VNS. The
same good results were found by Nagarajan et al.9
In this study, the children had multiple seizure char-
acteristics and the majority had a moderate to se-
vere mental handicap yet 25% of this prognostically
unfavourable group achieved a seizure reduction of
more than 90%. Again a baseline period of 1 month
was used. The results in terms of more than 50%
seizure frequency reduction were nevertheless re-
produced by Zamponi et al.10 in which of the 13
children with intractable epilepsy, multiple seizure
characteristics, mixed aetiology and moderate to
severe mental handicap in all, 66% of the children
experienced a seizure reduction of 50% or more.
In this case, a baseline period of 3 months was
used.
George et al.3 reported that the effects of VNS
are positively correlated to the length of the treat-
ment period. However, in our group of patients we
could not ﬁnd a relation between duration of stim-
ulation and treatment effect. The relative seizure
increase in the second year of treatment might be
attributed to a temporary deterioration of ﬁve chil-
dren in the 15th month.
As VNS did not inﬂuence cognitive measure and
quality of life measurements unfavourably, it may
be justiﬁed to conclude that VNS does not have any
adverse effects on higher order functions or quality
of life, even at long term (Table 3). This conﬁrms
the clinical anecdotal information and may be im-
portant for parents with regard to the treatment
of their child. In addition, there was a mild im-
provement in mental age, although the change of
4.2 months is modest compared to the 24 months
of follow-up. Also the results of behavioural and
cognitive function at 24 months are similar to the
follow-up results after 6 months of VNS. In this spe-
ciﬁc patient population efﬁcacy of VNS apparently
does not increase with the duration of treatment.30
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Our results at 6-month follow-up also revealed
a positive effect of VNS on behaviour independent
of seizure control. These ﬁndings are supported by
those of Lundgren et al.,6 Dodrill and Morris31 and
Parker et al.8 We suggested that this may be in-
terpreted as a direct (positive) effect of VNS on
behaviour.32 Further follow-up showed that this ef-
fect did not persist over time and decline by the end
of the study. Table 4 shows that group 3 (the group
without any effects of VNS on seizure frequency)
still improved in mental age even though this effect
is modest (1.7 months) and smaller than that found
at the 6-month follow-up (29 months). This may be
due to the speciﬁc group in our study that had se-
vere mental handicaps thereby causing a ‘ceiling’
effect on the response to treatment. Thus, it may
be worthwhile to test the direct effects of VNS on
behaviour in a group of epileptic children who are
not mentally retarded.
To date there is only limited information on the
characteristics of patients who respond to VNS.
Ben Menachem et al. described differences be-
tween responders and non-responders based on
the ﬁndings of a long-term follow-up observa-
tional study 4. They reported that 50% of the pa-
tients with a right-sided focus (n = 16) responded
whereas only 25% of those with a left-sided focus
did so (n = 12). Eight patients could be classiﬁed as
Lennox—Gastaut, suffering mainly from generalised
tonic—clonic seizures and absences. Of these, ﬁve
responded. Patients with atonic seizures did not
respond but of the nine patients with primary gen-
eralised epilepsy ﬁve responded: they all suffered
from absence seizures exclusively.
There is also an indication that baseline seizure
frequency has its impact on the response to VNS.
Thus, the higher the baseline seizure frequency, the
better the responsiveness to VNS.33—35
In the present study, the four children who re-
sponded to VNS in terms of seizure frequency re-
duction had the highest frequency of baseline back-
ground activity, the lowest quantity of interictal
epileptic activity and highest mental level at base-
line as compared to non-responders. These three
factors might be interpreted as a measure of brain
function. The lower the frequency of background
activity and the higher the interictal activity the
higher the degree of brain damage.
The absence seizures seem to respond better than
other seizure types.
The best treatment effect was found in the
group with highest mental age at baseline (89.3
months for responders versus 15.0/20.3 months
for non-responders; P = 0.04). Mental retardation
can, therefore, be characterised as a negative
prognostic factor for treatment with VNS.
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